Developing Drug Products in an Aging Society: From Concept to Prescribing (AAPS Advances in the Pharmaceutical Sciences Series Book 24)

This book aims to address the major aspects of future drug product development and therapy for older adults, giving practical guidance for the rational product and clinical development and prescribing of drug products to this ever growing segment of the population. With authors coming from key “aging” markets such as Europe, the USA, China and Japan, the book will provide valuable information for students, scientists, regulators, practitioners, and other healthcare professionals from academia, industry and regulatory bodies. Front Matter....Pages i-xviii Front Matter....Pages 1-1 Healthcare Provisions in an Aging Society: U.S. Perspective....Pages 3-21 Healthcare Provision in an Aging Society—The European Perspective....Pages 23-44 Healthcare Provisions in the Aging Society: Japanese Perspectives....Pages 45-57 Front Matter....Pages 59-59 Old, Very Old and Frail....Pages 61-66 Age and the Process of Aging....Pages 67-86 Comprehensive Geriatric Assessment....Pages 87-101 Patients’ Clinical Characteristics, Disease Experience, and Perception....Pages 103-113 Front Matter....Pages 115-115 Ethical Considerations in Performing Clinical Trials in and for Older People....Pages 117-128 Patient Reported Outcomes in Clinical Trials and Practice with Older Patients....Pages 129-138 Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population....Pages 139-151 The Expectation to Treatment Model: A Framework for Adherence and Effectiveness....Pages 153-170 Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People....Pages 171-188 Front Matter....Pages 189-189 Defining Patient Centric Drug Product Design and Its Impact on Improving Safety and Effectiveness....Pages 191-216 Dosing Considerations in Older Adults....Pages 217-224 Oral Drug Product Use in the Elderly Patient Population....Pages 225-246 Drug Product Development for Older Adults—Multiparticulate Formulations....Pages 247-278 Parenteral Drug Delivery for Older Patients....Pages 279-290 Inhalation and Nasal Formulations....Pages 291-329 Ophthalmic Drug Development and the Elderly....Pages 331-382 Front Matter....Pages 383-401 Developing Drug Administration Devices for Geriatric Use....Pages 189-189 Manufacturing Platforms for Patient-Centric Drug Products....Pages 403-446 Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products....Pages 447-483 Front Matter....Pages 485-515 Prescribing to Older Adults....Pages 517-517 Multimorbidity and Polypharmacy....Pages 519-547 Vaccination in Older Adults....Pages 549-561 Medication Reviews in Older Adults....Pages 563-576 The Personalization of Drug Therapy for Elderly Patients....Pages 577-588 Importance of Clinical Nutrition in Therapy to Older Adults....Pages 589-611 Front Matter....Pages 613-625 Managing Drug Therapy of Older Patients in Primary and Secondary Care....Pages 627-627 Medication Adherence and Monitoring....Pages 629-657 Medication Compounding in the Provision of Drug Therapy....Pages 659-674 Geriatric Pharmacotherapy: Optimisation Through Integrated Approach in the Hospital Setting....Pages 675-682 Front Matter....Pages 683-697 European Medicines Agency (EMA): Regulatory Perspectives on Geriatric Medicines....Pages 699-699 Views on the Therapeutic Needs of Older Adults....Pages 701-717 Front Matter....Pages 719-734 Future Perspectives in Drug Therapy of Older Adults....Pages 735-735 Opportunities in Drug Product Development in an Aging Population....Pages 737-757 Back Matter....Pages 759-767 ....Pages 769-771 This book aims to address the major aspects of future drug product development and therapy for older adults, giving practical guidance for the rational product and clinical development and prescribing of drug products to this ever growing segment of the population. With authors coming from key 2aging3 markets such as Europe, the USA, China and Japan, the book will provide valuable information for students, scientists, regulators, practitioners, and other healthcare professionals from academia, industry and regulatory bodies